Home
Categories
DMD
Research
Press Releases
Approved Treatments
Editorials
Family Stories
Cures
WhatsApp Channel
About Us
Contact
Search
Home
Categories
DMD
Research
Press Releases
Approved Treatments
Editorials
Family Stories
Cures
WhatsApp Channel
About Us
Contact
More
Search
Home
Tags
Exon 44
Exon 44
Editorials
Del-zota (EXPLORE44) Provides Nearly 30% Normal Dystrophin Production in Patients Amenable to Exon 44 Skipping
Press Releases
Avidity Biosciences Announces Positive Topline Del-zota Data Showing Consistent, Statistically Significant Improvements in Dystrophin
Press Releases
Entrada Therapeutics Receives FDA Approval to Begin Clinical Trial of ENTR-601-44 Exon Skipping Treatment
Research
Upcoming Exon 44 Skipping Therapies for the Treatment of Duchenne Muscular Dystrophy
Press Releases
Entrada Therapeutics Receives UK Authorization to Begin ELEVATE-44-201
Research
Nippon Shinyaku Releases First Clinical Trial (First in Human) of Brogidirsen NS-089/NCNP-02 for the Treatment of Duchenne
Popular
Frequently Asked Questions About Elevidys Used for Duchenne Muscular Dystrophy
DMD Warrior
-
December 26, 2024
Must Read
Press Releases
Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-251 in Duchenne Muscular Dystrophy
Press Releases
Agamree (vamorolone) will be Covered in Slovenia by the Slovenian Health Insurance Fund
Press Releases
Russia-Based Circle of Kindness Foundation Announces 18% Price Cut for Elevidys Gene Therapy